Abstract
Purpose
Data on endothelial derangements in patients with non-functioning adrenal incidentaloma (NFAI) are scarce.
Methods
We investigated if NFAI patients present clinical, biochemical and endothelial alterations compared to individuals without an adrenal lesion and also the associations among these variables. Forty-two NFAI and 40 controls were evaluated. NFAI diagnosis and controls were defined according to the current guidelines and based on a normal adrenal imaging exam, respectively. Body composition was evaluated by dual emission X-ray absorptiometry. Endothelial reactivity was assessed by two methods: tonometry (Endo-PAT®) and laser speckle contrast imaging (LSCI).
Results
There were no differences between groups regarding age, gender, ethnicity, smoking status, and statin use. The frequency of metabolic syndrome according to the International Diabetes Federation criteria was 69% and 57.9%, respectively in NFAI and controls (p = 0.36), whereas the atherosclerotic cardiovascular disease (ASCVD) risk was 63.4% and 66.7% (p = 0.81). The clinical, laboratory, and anthropometric characteristics, as well as body composition, were similar between the groups. Additionally, any differences between groups were observed on endothelial reactivity tests. Nevertheless, we noted an association between cortisol levels after 1 mg-dexamethosone suppression test (1 mg-DST) and the duration of post-occlusive reactive hyperemia tested on microcirculation (r = 0.30; p = 0.03). NFAI patients require more antihypertensive drugs to achieve blood pressure control (p = 0.04). The number of antihypertensive drugs used to control blood pressure correlated with cortisol levels after 1 mg-DST (r = 0.29; p = 0.03).
Conclusions
Since both groups herein investigated had a high frequency of metabolic syndrome and ASCVD risk, it might explain similarities observed on endothelial reactivity. Nevertheless, prolonged reactive hyperemia response on microcirculation was correlated with cortisol levels under suppression.
This is a preview of subscription content, access via your institution.

References
- 1.
Barzon L, Sonino N, Fallo F, Palu G, Boscaro M (2003) Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol Euro Fed Endocr Soc 149(4):273–285
- 2.
Morelli V, Reimondo G, Giordano R, Della Casa S, Policola C, Palmieri S, Salcuni AS, Dolci A, Mendola M, Arosio M, Ambrosi B, Scillitani A, Ghigo E, Beck-Peccoz P, Terzolo M, Chiodini I (2014) Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab 99(3):827–834. https://doi.org/10.1210/jc.2013-3527
- 3.
Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, Mosconi C, Golfieri R, Paccapelo A, Pagotto U, Pasquali R (2014) Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabet Endocrinol 2(5):396–405. https://doi.org/10.1016/S2213-8587(13)70211-0
- 4.
Divison Garrote JA, Segui Diaz M, Escobar Cervantes C (2014) Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis. Semergen 40(7):399–400. https://doi.org/10.1016/j.semerg.2014.06.019
- 5.
Sbardella E, Minnetti M, D'Aluisio D, Rizza L, Di Giorgio MR, Vinci F, Pofi R, Giannetta E, Venneri MA, Vestri A, Morelli S, Lenzi A, Isidori AM (2018) Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Euro J Endocrinol Euro Fed Endocr Soc 178(5):501–511. https://doi.org/10.1530/EJE-17-0986
- 6.
Peppa M, Koliaki C, Raptis SA (2010) Adrenal incidentalomas and cardiometabolic morbidity: an emerging association with serious clinical implications. J Intern Med 268(6):555–566. https://doi.org/10.1111/j.1365-2796.2010.02291.x
- 7.
Di Dalmazi G, Pasquali R (2015) Adrenal adenomas, subclinical hypercortisolism, and cardiovascular outcomes. Curr Opin Endocrinol Diabetes Obes 22(3):163–168. https://doi.org/10.1097/MED.0000000000000153
- 8.
Arruda M, Mello Ribeiro Cavalari E, Pessoa de Paula M, Fernandes Cordeiro de Morais F, Furtado Bilro G, Alves Coelho MC, de Oliveira e Silva de Morais NA, Choeri D, Moraes A, Vieira Neto L (2018) The presence of nonfunctioning adrenal incidentalomas increases arterial hypertension frequency and severity, and is associated with cortisol levels after dexamethasone suppression test. J Hum Hypertens 32(1):3–11. https://doi.org/10.1038/s41371-017-0011-4
- 9.
Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A (2003) Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107(22):2805–2809. https://doi.org/10.1161/01.CIR.0000072765.93106.EE
- 10.
Mihailidou AS, Loanle TY, Mardini M, Funder JW (2009) Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54(6):1306–1312. https://doi.org/10.1161/HYPERTENSIONAHA.109.136242
- 11.
Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A (2010) Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 31(9):1142–1148. https://doi.org/10.1093/eurheartj/ehq010
- 12.
Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of adrenal tumors. Euro J Endocrinol Euro Fed Endocr Soc 175(2):G1–G34. https://doi.org/10.1530/EJE-16-0467
- 13.
Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD (2014) Adrenocortical carcinoma. Endocr Rev 35(2):282–326. https://doi.org/10.1210/er.2013-1029
- 14.
Gilbert R, Lim EM (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. Clin Biochem Rev Aust Assoc Clin Biochem 29(3):103–106
- 15.
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr (2016) The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:1889–916. doi:10.1210/jc.2015–4061
- 16.
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine S (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915–1942. https://doi.org/10.1210/jc.2014-1498
- 17.
Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee (1995). World Health Organization technical report series 854:1–452
- 18.
Nishida C, Ko GT, Kumanyika S (2010) Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. Eur J Clin Nutr 64(1):2–5. https://doi.org/10.1038/ejcn.2009.139
- 19.
Marathe PH, Gao HX, Close KL (2017) American diabetes association standards of medical care in diabetes 2017. J Diabet 9(4):320–324. https://doi.org/10.1111/1753-0407.12524
- 20.
Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med J Br Diabet Assoc 23(5):469–480. https://doi.org/10.1111/j.1464-5491.2006.01858.x
- 21.
Robinson JG, Stone NJ (2015) The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J 36(31):2110–2118. https://doi.org/10.1093/eurheartj/ehv182
- 22.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice G (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):S1–45. https://doi.org/10.1161/01.cir.0000437738.63853.7a
- 23.
Barbosa Mdo C, Bouskela E, Cyrino FZ, Azevedo AP, Costa MC, de Souza M, Santos DS, Barbosa FL, Guerra LF, Nascimento Mdo D (2012) Effects of babassu nut oil on ischemia/reperfusion-induced leukocyte adhesion and macromolecular leakage in the microcirculation: observation in the hamster cheek pouch. Lipids Health Dis 11:158. https://doi.org/10.1186/1476-511X-11-158
- 24.
Axtell AL, Gomari FA, Cooke JP (2010) Assessing endothelial vasodilator function with the Endo-PAT 2000. J Vis Exp 44:2167. https://doi.org/10.3791/2167
- 25.
Mahe G, Durand S, Humeau-Heurtier A, Leftheriotis G, Abraham P (2012) Impact of experimental conditions on noncontact laser recordings in microvascular studies. Microcirculation 19(8):669–675. https://doi.org/10.1111/j.1549-8719.2012.00205.x
- 26.
Souza EG, De Lorenzo A, Huguenin G, Oliveira GM, Tibirica E (2014) Impairment of systemic microvascular endothelial and smooth muscle function in individuals with early-onset coronary artery disease: studies with laser speckle contrast imaging. Coron Artery Dis 25(1):23–28. https://doi.org/10.1097/MCA.0000000000000055
- 27.
Tibirica E, Matheus AS, Nunes B, Sperandei S, Gomes MB (2011) Repeatability of the evaluation of systemic microvascular endothelial function using laser Doppler perfusion monitoring: clinical and statistical implications. Clinics 66(4):599–605
- 28.
Kelly TL, Wilson KE, Heymsfield SB (2009) Dual energy X-ray absorptiometry body composition reference values from NHANES. PLoS ONE 4(9):e7038. https://doi.org/10.1371/journal.pone.0007038
- 29.
Cruz-Jentoft AJ, Landi F, Schneider SM, Zuniga C, Arai H, Boirie Y, Chen LK, Fielding RA, Martin FC, Michel JP, Sieber C, Stout JR, Studenski SA, Vellas B, Woo J, Zamboni M, Cederholm T (2014) Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 43(6):748–759. https://doi.org/10.1093/ageing/afu115
- 30.
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763
- 31.
Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, Ferrucci L, Guralnik JM, Fragala MS, Kenny AM, Kiel DP, Kritchevsky SB, Shardell MD, Dam TT, Vassileva MT (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol Ser A Biol Sci Med Sci 69(5):547–558. https://doi.org/10.1093/gerona/glu010
- 32.
Yilmaz H, Tutuncu NB, Sahin M (2009) Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest 32(11):913–916. https://doi.org/10.3275/6431
- 33.
Comlekci A, Yener S, Ertilav S, Secil M, Akinci B, Demir T, Kebapcilar L, Bayraktar F, Yesil S, Eraslan S (2010) Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience. Endocrine 37(1):40–46. https://doi.org/10.1007/s12020-009-9260-5
- 34.
Ribeiro Cavalari EM, de Paula MP, Arruda M, Carraro N, Martins A, de Souza K, Coelho MC, de Oliveira ESdMNA, Moraes AB, Vieira Neto L (2018) Nonfunctioning adrenal incidentaloma: a novel predictive factor for metabolic syndrome. Clin Endocrinol. https://doi.org/10.1111/cen.13822
- 35.
Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (2016) “Nonfunctional” adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med 165(8):533–542. https://doi.org/10.7326/M16-0547
- 36.
Wagnerova H, Dudasova D, Lazurova I (2009) Hormonal and metabolic evaluation of adrenal incidentalomas. Neoplasma 56(6):521–525. https://doi.org/10.4149/neo_2009_06_521
- 37.
Morelli V, Aresta C, Gaudio A, Eller-Vainicher C, Zhukouskaya VV, Merlotti D, Orsi E, Maria Barbieri A, Fustinoni S, Polledri E, Gennari L, Falchetti A, Carnevale V, Persani L, Scillitani A, Chiodini I (2020) Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu. Endocrine 68(2):411–419. https://doi.org/10.1007/s12020-020-02212-9
- 38.
Debono M, Newell-Price J (2015) Subclinical hypercortisolism in adrenal incidentaloma. Curr Opin Endocrinol Diabetes Obes 22(3):185–192. https://doi.org/10.1097/MED.0000000000000151
- 39.
Di Dalmazi G, Vicennati V, Rinaldi E, Morselli-Labate AM, Giampalma E, Mosconi C, Pagotto U, Pasquali R (2012) Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Euro J Endocrinol Euro Fed Endocr Soc 166(4):669–677. https://doi.org/10.1530/EJE-11-1039
- 40.
Kraemer-Aguiar LG, Laflor CM, Bouskela E (2008) Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metab Clin Exper 57(12):1740–1746. https://doi.org/10.1016/j.metabol.2008.07.034
- 41.
Kraemer-Aguiar LG, Maranhao PA, Sicuro FL, Bouskela E (2010) Microvascular dysfunction: a direct link among BMI, waist circumference and glucose homeostasis in young overweight/obese normoglycemic women? Intern J Obes 34(1):111–117. https://doi.org/10.1038/ijo.2009.209
- 42.
Moerland M, Kales AJ, Schrier L, van Dongen MG, Bradnock D, Burggraaf J (2012) Evaluation of the EndoPAT as a tool to assess endothelial function. Intern J Vasc Med 2012:904141. https://doi.org/10.1155/2012/904141
- 43.
Wang X, Keith JC Jr, Struthers AD, Feuerstein GZ (2008) Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther 26(3):214–223. https://doi.org/10.1111/j.1755-5922.2008.00051.x
- 44.
Kvernmo HD, Stefanovska A, Bracic M, Kirkeboen KA, Kvernebo K (1998) Spectral analysis of the laser Doppler perfusion signal in human skin before and after exercise. Microvasc Res 56(3):173–182. https://doi.org/10.1006/mvre.1998.2108
- 45.
Rossi R, Grimaldi T, Origliani G, Fantini G, Coppi F, Modena MG (2002) Menopause and cardiovascular risk. Pathophysiol Haemost Thromb 32(5–6):325–328. https://doi.org/10.1159/000073591
- 46.
Eun HC (1995) Evaluation of skin blood flow by laser Doppler flowmetry. Clin Dermatol 13(4):337–347. https://doi.org/10.1016/0738-081x(95)00080-y
- 47.
de Carvalho VF, Bressan J, Babio N, Salas-Salvado J (2013) Prevalence of metabolic syndrome in Brazilian adults: a systematic review. BMC Public Health 13:1198. https://doi.org/10.1186/1471-2458-13-1198
- 48.
Barahona MJ, Sucunza N, Resmini E, Fernandez-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM (2009) Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab 94(9):3365–3371. https://doi.org/10.1210/jc.2009-0766
- 49.
Delivanis DA, Iniguez-Ariza NM, Zeb MH, Moynagh MR, Takahashi N, McKenzie TJ, Thomas MA, Gogos C, Young WF, Bancos I, Kyriazopoulou V (2018) Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in patients with adrenal adenomas. Clin Endocrinol 88(2):209–216. https://doi.org/10.1111/cen.13512
- 50.
Chin SO, Rhee SY, Chon S, Hwang YC, Jeong IK, Oh S, Ahn KJ, Chung HY, Woo JT, Kim SW, Kim JW, Kim YS, Ahn HY (2013) Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PLoS ONE 8(3):e60119. https://doi.org/10.1371/journal.pone.0060119
- 51.
Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A (2000) Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2(1):64–70. https://doi.org/10.1007/s11906-000-0061-8
- 52.
Judd AM, Call GB, Barney M, McIlmoil CJ, Balls AG, Adams A, Oliveira GK (2000) Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann N Y Acad Sci 917:628–637. https://doi.org/10.1111/j.1749-6632.2000.tb05428.x
- 53.
Willenberg HS, Path G, Vogeli TA, Scherbaum WA, Bornstein SR (2002) Role of interleukin-6 in stress response in normal and tumorous adrenal cells and during chronic inflammation. Ann N Y Acad Sci 966:304–314. https://doi.org/10.1111/j.1749-6632.2002.tb04230.x
- 54.
Pacurari M, Kafoury R, Tchounwou PB, Ndebele K (2014) The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Intern J Inflam 2014:689360. https://doi.org/10.1155/2014/689360
- 55.
Harman E, Karadeniz M, Biray C, Zengi A, Cetinkalp S, Ozgen AG, Saygili F, Berdeli A, Gunduz C, Yilmaz C (2009) The relation of adiponectin and tumor necrosis factor alpha levels between endothelial nitric oxide synthase, angiotensin-converting enzyme, transforming growth factor beta, and tumor necrosis factor alpha gene polymorphism in adrenal incidentalomas. J Endocrinol Invest 32(11):881–888. https://doi.org/10.3275/6279
- 56.
Duprez DA (2006) Role of the renin–angiotensin–aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 24(6):983–991. https://doi.org/10.1097/01.hjh.0000226182.60321.69
- 57.
Ermetici F, Malavazos AE, Corbetta S, Morricone L, Dall'Asta C, Corsi MM, Ambrosi B (2007) Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metab Clin Exp 56(5):686–692. https://doi.org/10.1016/j.metabol.2006.12.018
Acknowledgements
This study was made possible thanks to grants from the Research Support Foundation of the State of Rio de Janeiro (FAPERJ) and the Brazilian National Council for Scientific and Technological Development (CNPq).
Author information
Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflict of interest in this work.
Ethical approval
All procedures involving human participants were performed in accordance with the ethical standards of the Institutional Ethics Committee at which the studies were conducted. This paper does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
de Paula, M.P., Moraes, A.B., de Souza, M.G.C. et al. Cortisol level after dexamethasone suppression test in patients with non-functioning adrenal incidentaloma is positively associated with the duration of reactive hyperemia response on microvascular bed. J Endocrinol Invest 44, 609–619 (2021). https://doi.org/10.1007/s40618-020-01360-z
Received:
Accepted:
Published:
Issue Date:
Keywords
- Adrenal incidentaloma
- Nonfunctioning adrenal incidentaloma
- Endothelial dysfunction
- Cytokines
- Cardiovascular risk